

COSENTYX (SECUKINUMAB) INFUSION ORDERS

P: 877.365.5566 | F: 855.889.2946

A Carelon Company			P : 077.303.	5500 F i 655.60	59.2940
PATIENT IN	FORMATION:	Fax completed form	, insurance information, and o	clinical documentation to 8	55.889.2946
Patient Name:			DOB:	Phone:	
		Continuing The	rapy Next Treatment	Date:	
MEDICAL IN	IFORMATION				
] Psoriatic Arthritis] Ankylosing Spond] Other:	ylitis (AS)	radiographic axial spo _)	ondyloarthritis (nr-a	xSpA)
ICD-10 Code:					
Patient Weigl	ht: lbs. (red	quired) Allergies	5:		
THERAPY O	RDER				
☐ 1.75mg/kg	at Week 0, followe IV every 4 weeks x mance dose (1.75m	1 year	V every 4 weeks there	eafter x 1 year	
) Required labs] TB QFT screening	g yearly] Paragon 🛛 Re	ency: D Every infusion	on 🗌 Other:	
 Epinephrine >30kg 15-30kg Diphenhydra NS 1000mL Refer to phy 	g (33-66lbs): EpiPen Jr. (Imine: Administer 25-50 PRN per protocol (adult) sician order or institutior	or compounded syring D.15mg or compounde mg orally OR IV (adult) nal protocol for pediat		repeat in 5-10 minutes x	1
PROVIDER	NFORMATION				
agent in dealing with me	dical and prescription insurance co	mpanies, and to select the prefe	and its employees to serve as your pric rrred site of care for the patient. Jre: Cont ax: Cont , please list site of care)		
PREFERRED	LOCATION				
City:	State	2:	View our locations her	e:	
	s fax is intended to be delivered o	PARAGONHEA	LTHCARE.COM	nivilaged property or exampt from	n disclosuro undor

IMPORTANT N delivered only to the named address and conta confidential, privileged prope material that is a applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





A Carelon Company

PATIENT INFORMATION:

Patient Name: DOB:
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL
Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)
Include patient demographic information and insurance information
Include patient's medication list
Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
☐ Has the patient had a documented contraindication/intolerance or failed trial of a DMARD, NSAID, or conventional therapy (i.e., MTX, leflunomide)? ☐ Yes ☐ No If yes, which drug(s)?
□ Does the patient have a contraindication/intolerance or failed trial to at least one biologic (i.e., Humira, Enbrel, Stelara, Cimzia)? □ Yes □ No If yes, which drug(s)?
Include labs and/or test results to support diagnosis (attach results)
CRP and/or ESR
Other applicable diagnostic testing and/or labs
<i>If applicable</i> - Last known biological therapy: and last date received: If patient is switching to biologic therapies, please perform a washout period of weeks prior to starting Cosentyx.
Other medical necessity:

REQUIRED PRE-SCREENING

□ TB screening test completed within 12 months - attach results
 □ Positive □ Negative

If TB results are positive - please provide documentation of treatment or medical clearance, and a negative CXR

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.